Lymphoma Clinical Trials in Dallas

Showing 361-380 of 450 trials

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

NCT00741403

An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose (MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three consecutive weeks in cancer patients The objectives of this study are: * To determine the safety and MTD of CPI-613 when administered 2x weekly for 3 consecutive weeks. * To determine pharmacokinetics of CPI-613 following intravenous (IV) administration. * To observe the anti-tumor effects of CPI-613, if any occur.

Advanced CancerMetastatic CancerLymphoma+2 more

Cornerstone Pharmaceuticals39 participantsStarted Aug 2008

Peoria, Arizona, United States • The Bronx, New York, United States • Dallas, Texas, United States +1 more locations

COMPLETEDPhase 1/2< 1 mile

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT00006029

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed or refractory Hodgkin's lymphoma.

Lymphoma

Alliance for Clinical Trials in Oncology91 participantsStarted Jul 2000

Anniston, Alabama, United States • La Jolla, California, United States • San Diego, California, United States +73 more locations

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Lymphoma Trials in Other Cities

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Cladribine in Patients With Mantle Cell Lymphoma

Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

Other Conditions in Dallas